Vivine: iSert® Model XC1 Model XY1

Preloaded System as low as 2.0 mm incision

Vivinex iSert®

Long-term quality of vision is what every patient expects

Innovative HOYA technology provides: • New Hydrophobic Acrylic material • Outstanding performances • For long-lasting ophthalmic surgical outcomes

Model XC1 Model XY1

Long-term quality of vision is what every patient expects

Innovative HOYA technology provides:

- New Hydrophobic Acrylic material
- **Outstanding** performances
- For long-lasting ophthalmic surgical outcomes

Singularly Focused. Globally Powered.[™]

HOYA Surgical Optics names and logos are registered trademarks of HOYA Surgical Optics, Inc. © 2015 HOYA Surgical Optics, Inc. All rights reserved.

HOYA Surgical Optics GmbH | De-Saint-Exupéry-Str. 8 | 60549 Frankfurt am Main | Germany HOYA.com/SurgicalOptics





2015-07-09_HSOE_XC1/XY1_BR_EN_01









Model XY1


Quality for Long-term Vision

Cutting-edge IOL* technology provides research-driven benefits to protect your patients' "long-term vision quality'



Long-term Transparency

According to in vitro tests, the new acrylic polymers properties of **Vivinex[™]** drastically reduce glistening




- 1. Nishi O, Nishi K, Akura J. Speed of capsular bend formation at the optic edge of acrylic, silicone, and poly(methyl methacrylate) lenses. J Cataract Refract Surg 2002; 28(3):431-437.
- 2. Meacock W, et al. The Effect of Texturing the Intraocular Lens Edge on Postoperative Glare Symptoms. Archives of Ophthalmology 2002; Vol 120: 1294-1298.
- 3. Data on file
- * IOL = Intra-Ocular Lens

- 4. Data on file: in vitro test achieved according to published method: Marrie van der Mooren et al. "Effects of glistening in intraocular lens", BIOMEDICAL OPTICS EXPRESS, vol 4, No.8, P1294-1304(2013).
- 5. Data on file



• No glistening was seen based on in vitro testing (35°C to 23°C)⁴ The innovative hydrophobic material Vivinex[™] is associated with a significant decrease in glistening



PCO** reduction proven in *in vivo* tests

in vivo test on rabbit eyes shows that proprietary surface treatment offers strong PCO reduction⁶

PCO reduction proven in human eyes Clinical outcome shows very low PCO rate in post-operative time⁷

• Strong capsular adhesion reduced the risk of PCO

material


• Rabbits receiving lenses with proprietary surface treatment showed a low level of PCO

• Effective long-term PCO inhibition

ONG TERA


• 30 eyes were enrolled and YAG rate was 3.3% at 3 years post-operative time⁸


Year 1



same acrylic material as control + surface treatment Patient А

Patient В





Patient С




Images courtesy of Hiroyuki Matsushima, MD, PhD, Department of Ophthalmology, Dokkyo Medical University, Japan

6. Hiroyuki Matsushima, et al. Active oxygen processing for acrylic intraocular lenses to prevent.posterior capsule opacification. J Cataract Refract Surg. 2006; 32:1035-1040.

** PCO = Posterior Capsule Opacification

- 7. Japanese clinical study carried out in 2010 : internal report
- 8. Hiroyuki Matsushima, Dokkyo Medical University. Presented at 68th Annual Congress of Japan Clinical Ophthalmology; November 13, 2014 Kobe Japan




Easy to insert through an incision as low as **2.0 mm** The ergonomically-designed **iSert**[®] system provides highly predictable, reproducible IOL delivery through a very small incision

ONGTER PERFORMANCE

Vivinex[™] iSert[®]: The innovative 1-piece acrylic lens for long term patient satisfaction The HOYA surface treatment on the posterior surface and the new feature of the **Vivinex[™] iSert[®]** design provides outstanding performances

Textured-rough hapti

Easy to insert through an incision as low as 2.0 mm



- New **iSert**[®] offers easy handling and a better surgical comfort
- Very small incision size reduces the risk of surgically-induced astigmatism

Step A Infuse the OVD into the injector through the infusion port with the cannula pointed in a direction perpendicular to the body. Fill up the area indicated by dotted lines with the OVD and confirm that the OVD has covered the entire

intraocular lens.



Step B Press the release tabs, lift up and remove the cover from the case.

	Model	Vivinex™ iSert® XC1 Vivinex™ iSert® XY1
	Optic Design	Aspheric "ABC Design" with sharp textured optic edge
n	Optic & Haptic Materials	Hydrophobic acrylic (Vivinex™) with UV filtering (Model XC1) with blue light filtering (Model XY1)
	Haptic Design	Textured-rough haptic surface
ın"	Dimension (Optic/OAL)	6.0 mm/13.0 mm
	Power	+6.0 to +30.0 D (in 0.5 D increments)
	Incision size	as low as 2.0 mm





Step C

13 0 mn

Push the slider slowly until it stops, holding the body with your thumb. Remove the injector from the case.



ONGTER

PERFORMANCE

Step D

Carefully insert the nozzle into the eye through the incision, keeping bevel down. Slowly rotate the screw plunger to inject the lens into the capsular bag.